Acetyl-L-carnitine for research subjects with hepatic encephalopathy [PMID: 30610762] Laboratory literature summary: Acetyl-L-carnitine for research subjects with hepatic encephalopathy
The move follows a surge in Ozempic being dispensed to Americans, it said
B., Renstrm, F., Aczl, S., Folie, P., Biraima-Steinemann, M., Beuschlein, F., & Bilz, S
At a glance Mechanism / activates GIP, GLP-1, and glucagon receptors Research phase / phase 3 clinical development Published obesity evidence / randomized phase 2 trial in 338 adults Key research questions / durability, long-term outcomes, and uncommon adverse events Current research status No state or commercial program changes retatrutide's federal investigational status
Simonetti, MD, a medical weight loss specialist at University of Utah Health